Targets › TNNC1
1 program from 1 company in 4 trials: 3 Phase 3, 1 Phase 4; Cardiovascular, Other; next expected readout Jun 2028.
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments. (UniProt, P63316)
Open in Phaseline: the race on TNNC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tenax Therapeutics | Levosimendan (TNX-103) Phosphodiesterase 3 inhibitor; Troponin, cardiac muscle positive modulator | PDE3A, PDE3B, TNNC1, TNNI3, TNNT2 | Phase 3 | Pulmonary Hypertension Associated With HFpEF; Pulmonary Hypertension; Mechanical Ventilation; Cardiogenic Shock | Jun 2028 |
Pulmonary Hypertension Associated With HFpEF (1) Pulmonary Hypertension (1) Mechanical Ventilation (1) Cardiogenic Shock (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.